Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Dual Biologic Therapy for Severe Hidradenitis Suppurativa

Description

The speaker discusses using dual biologic or biologic-plus-JAK therapy for severe hidradenitis suppurativa (HS) when single-agent biologics reach an efficacy ceiling and patients remain functionally impaired. She argues that for the most severe cases, 50% improvement is often not enough, and that adding a second targeted therapy may provide additive benefit and help reduce reliance on antibiotics, prednisone, and frequent flares. She presents a case of a man with Hurley stage 3 HS who improved partially on upadacitinib, then had marked additional improvement after adding bimekizumab, with reduced drainage, pain, and new lesions over nearly two years of stable control. She reviews limited HS data and supporting evidence from other specialties, noting that some combination regimens, such as TNF plus IL-17 or TNF plus IL-23/JAK, appear reasonably safe in available studies, while TNF plus IL-1 raises more concern for serious infection. Another case highlights a patient on adalimumab plus secukinumab who developed a nocardia infection, underscoring the need for close infection vigilance. Practical guidance includes discussing off-label use transparently, leveraging comorbidities for insurance coverage, considering patient preference for pills versus injections, planning vaccinations, using the most stringent lab monitoring required by the regimen, and reassessing whether the first agent can be tapered once the second agent demonstrates benefit.

View more

Conclusions

For severe hidradenitis suppurativa that remains functionally limiting despite one biologic, dual therapy can provide additive benefit and help patients reach a more meaningful level of disease control.
The presentation suggests that a second targeted agent is often preferable to repeatedly cycling monotherapies, antibiotics, or prednisone when a patient has hit an efficacy ceiling.
In the featured case, adding bimekizumab to upadacitinib produced sustained improvement in lesions, drainage, pain, and overall function over many months.
Dual biologic or biologic-plus-JAK therapy appears most justifiable in highly refractory HS patients with severe quality-of-life impairment rather than in milder disease.
Available case reports, case series, and extrapolated data from psoriasis, psoriatic arthritis, ulcerative colitis, and rheumatoid arthritis suggest combination immunomodulation can be effective and may have acceptable safety in selected patients.
Among the combinations discussed, TNF plus IL-17, IL-17 plus JAK1 inhibitor, and TNF plus IL-23/12-23 were presented as more plausible options.
The speaker cautioned against combining anti-TNF therapy with IL-1 inhibition because existing data show a higher serious infection risk.
A key safety conclusion is that infection must be actively considered whenever new skin findings or symptoms arise during dual immunomodulator therapy.
Successful use of dual therapy requires careful planning around insurance coverage, vaccine timing, lab monitoring, and documenting the baseline response to the first agent.
When dual therapy works, it may allow later tapering toward the minimum effective immunomodulatory dose while maintaining disease control and enabling surgical management such as deroofing.

Gastroenterol Hepatol (N.Y.), 2022; 18(4 Suppl 1): 9–10.
Finnegan et al. JAAD Case Reports. 2024.
Thibodeaux et al. JAAD Case Reports. 2019.
Thibodeaux et al. JAAD Case Reports, 2019.
Mease et al., Arthritis & Rheumatology, 2018.
Genovese et al. Arthritis & Rheumatism. 2004.